Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v3-EN | Version v2-FR | |
---|---|---|
Language | English | French |
Date Updated | 2020-07-30 | 2020-07-22 |
Drug Identification Number | 02474433 | 02474433 |
Brand name | OGIVRI | OGIVRI |
Common or Proper name | TRASTUZUMAB | TRASTUZUMAB |
Company Name | BIOSIMILAR COLLABORATIONS IRELAND LIMITED | BIOSIMILAR COLLABORATIONS IRELAND LIMITED |
Ingredients | TRASTUZUMAB WATER | TRASTUZUMAB WATER |
Strength(s) | 440MG 20ML | 440MG 20ML |
Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 1VL TRASTUZUMAB 1VL BWFI | 1VL TRASTUZUMAB 1VL BWFI |
ATC code | L01XC | L01XC |
ATC description | OTHER ANTINEOPLASTIC AGENTS | OTHER ANTINEOPLASTIC AGENTS |
Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
Anticipated start date | ||
Actual start date | 2020-07-17 | 2020-07-17 |
Estimated end date | 2020-08-04 | 2020-08-04 |
Actual end date | 2020-07-30 | |
Shortage status | Actual shortage | Actual shortage |
Tier 3 Status | No | No |
Company comments | Limited product supply is available on allocation | Limited product supply is available on allocation |
Health Canada comments |